Results 81 to 90 of about 125,062 (284)

Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score–Weighted Cohort Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Transthyretin cardiac amyloidosis results from the deposition of misfolded amyloid fibrils in cardiac tissue, leading to progressive heart failure.
Louise Zmuda, Amira Zaroui, Mounira Kharoubi, Emmanuelle Boutin, Frédéric Roca, Silvia Oghina, Emmanuel Teiger, Marie Laurent, Florence Canoui‐Poitrine, Thibaud Damy, Amaury Broussier   +10 more
doaj   +1 more source

The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis

Orphanet Journal of Rare Diseases, 2020
Background Immunoglobulin light chain (AL) amyloidosis is a rare, multi-systemic disorder characterized by two disease processes: an underlying plasma cell dyscrasia that provides the source of pathologic light chains, and the resulting organ dysfunction
The Inaugural Amyloidosis Forum Panelists, Isabelle Lousada   +1 more
doaj   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Anti-IL1 in patients with low penetrance mutations for autoinflammatory diseases: tuscany and sicilian case series from paediatric to adult age [PDF]

, 2017
Patients with low penetrance mutations for Autoinflammatory syndromes (AID) can have severe clinical manifestations, which require to be treated with biological drugs anti-IL-1.
Giovanni Corsello, Luca Cantarini, Maria Cristina Maggio, Rolando Cimaz, Umberto Corpora   +4 more
core  

Breast amyloidosis: a case report [PDF]

, 2016
Amyloidosis is an uncommon disorder characterized by extracellular deposition of abnormal proteins. Breast involvement has rarely been reported and can clinically be misdiagnosed as breast cancer.
Boscaini, Giulia, DE SANTIS, Giorgio, Pignatti, Marco, Tazzioli, Giovanni   +3 more
core   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

Reliability and validity of the Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire impact scales

Journal of Patient-Reported Outcomes
Background The diversity of disease phenotypes associated with transthyretin (ATTR) amyloidosis poses challenges for measurement of health outcomes. The Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire is a disease-specific patient ...
Andrew Lovley, Kristen Hsu, Kaitlin LaGasse, Isabelle Lousada, Kristen L. McCausland, Michelle K. Carty, Sabrina Rebello, Jakob B. Bjorner   +7 more
doaj   +1 more source

The non-coding RNA landscape of plasma cell dyscrasias [PDF]

, 2020
Despite substantial advancements have been done in the understanding of the pathogenesis of plasma cell (PC) disorders, these malignancies remain hard-to-treat.
Azab, Kareem A, et al,, Morelli, Eugenio, Rocca, Roberta   +3 more
core   +1 more source

Amyloidosis cutis dyschromica in two female siblings: cases report [PDF]

, 2011
Background Cutaneous amyloidosis has been classified into primary cutaneous amyloidosis (PCA, OMIM #105250), secondary cutaneous amyloidosis and systemic cutaneous amyloidosis.
Wenlin Yang, Yangyang Lin, Jian Yang, Wensheng Lin   +3 more
core   +1 more source